SHANDONG SINOBIOWAY BIOMEDICINE CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.59 CNY | +0.72% |
|
+2.03% | -13.77% |
| 2023 | Sinobioway Biomedicine's Unit to Relocate | MT |
| 2023 | Shandong Sinobioway Biomedicine Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 | CI |
| Sales 2021 | 403M 55.58M | Sales 2022 | 357M 49.28M | Capitalization | 10.39B 1.43B |
|---|---|---|---|---|---|
| Net income 2021 | 271M 37.4M | Net income 2022 | -14M -1.93M | EV / Sales 2021 | 34.9 x |
| Net cash position 2021 | 10.64M 1.47M | Net cash position 2022 | 18.45M 2.55M | EV / Sales 2022 | 29 x |
| P/E ratio 2021 |
52
x | P/E ratio 2022 |
-706
x | Employees | 666 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 58.78% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.72% | ||
| 1 week | +2.03% | ||
| Current month | +8.72% | ||
| 1 month | +13.12% | ||
| 3 months | +0.24% | ||
| 6 months | -17.01% | ||
| Current year | -13.77% |
1 week
12.18
12.74
1 month
10.7414.04
Current year
8.5414.81
1 year
8.5421.69
3 years
8.5425.68
5 years
5.5034.10
10 years
5.5042.49
| Managers | Title | Age | Since |
|---|---|---|---|
JiaLin Yue
CEO | Chief Executive Officer | 56 | 22-07-08 |
Yang Jun Liu
DFI | Director of Finance/CFO | 49 | 22-07-08 |
Hui Zhao
BRD | Director/Board Member | 55 | 22-04-09 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ai Hua Pan
CHM | Chairman | 66 | 15-12-14 |
Xue Ming Yan
BRD | Director/Board Member | 51 | 15-10-12 |
Wen Jun Liu
BRD | Director/Board Member | 41 | 22-07-08 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +2.22% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 12.59 | +0.72% | 4,027,521 |
| 24-04-24 | 12.5 | +0.64% | 3,385,600 |
| 24-04-23 | 12.42 | -0.16% | 2,954,900 |
| 24-04-22 | 12.44 | -0.24% | 3,222,427 |
| 24-04-19 | 12.47 | +1.05% | 3,824,225 |
End-of-day quote Shenzhen S.E., April 24, 2024
More quotes
Shandong Sinobioway Biomedicine Co Ltd, formerly Zibo Wanchang Science & Technology Co Ltd, is a China-based company principally engaged in the manufacturing of pharmaceuticals. The Company is engaged in the business of interferon, nerve growth factor, biopharmaceutical contract research organization (CRO)/pharmaceutical contract development and manufacturing enterprise (CDMO), vaccines and pharmaceutical intermediates. The Company's main products include anferon, encyclopedia, Corona Virus Disease2019 vaccine and others. The Company distributes its products within domestic market.
Sector
Pharmaceuticals
Calendar
2024-04-29
- Q4 2023 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| -13.77% | 1.15B | |
| -4.61% | 87.53B | |
| +2.63% | 40.42B | |
| -21.76% | 29.48B | |
| +58.56% | 25.43B | |
| -14.78% | 15.59B | |
| -18.49% | 11.49B | |
| -15.61% | 11.1B | |
| -44.02% | 11.3B | |
| +5.17% | 8.75B |
- Stock Market
- Equities
- 002581 Stock
